NeuroClnx at CTAD 2026

Nov 16–19, 2026 Boston, MA ~1.7k attendees Website

NeuroClnx takes part in 2 sessions at CTAD 2026 in Boston. Its program draws on its experience as a site in the AHEAD 3-45 programme. Its work covers blood test eligibility, APOE genotyping and amyloid confirmation, and the limits of cognitive prescreening for amyloid enrichment.

OrganizationCTAD 2026 Attendance
NeuroClnx
Glasgow, UK
Clinical trial sites
UK clinical research site network with clinics in Glasgow and Warrington running Alzheimer's and other neurology trials.
Poster
Mon Nov 16 – Tue Nov 17
2:00pm Mon – 5:30pm Tue

Explore the full CTAD 2026 dataset

Get in-depth attendee and institution profiles and research, to plan your meetings in Boston. Leave your work email and we’ll be in touch.

Privacy

Download the full CTAD 2026 CSV

Leave your work email and we’ll be in touch. The CSV adds attendee names, roles and contact details to the company and session data shown here.

Privacy

Instantly find 20 buyers from NeuroClnx

Get a list of who you should contact, their contact info, and what to say.

Totally free and instant, no sign up necessary!

Not affiliated with or endorsed by the CTAD Conference. Organization details are derived from CTAD’s published program, poster list and sponsor page. Submit a correction